Withdrawal of the Application to Change the EMA Marketing Authorisation for Pralsetinib
Application for extension of therapeutic indications concerned the use to treat patients from 12 years of age who have RET-mutated medullary thyroid cancer or RET fusion-positive thyroid cancer